TABLE 2.
Characteristics of patients with infective endocarditis due to VR E. faecalis
| Patient no., age (yr)/sexa (reference) | Predisposing heart conditionb | Valve(s) involvedb | Susceptibility datac | Vancomycin resistance phenotyped | Antibiotic therapy (duration [wk])c | Surgical interventionb | Outcome | Follow-upe |
|---|---|---|---|---|---|---|---|---|
| 1, 64/M (36) | AV prosthesis | AV | AMP (S), CIP (S), GEN (HLR) | NR | AMP + CIP (2) | No | Death | Death 2 wk after diagnosis of endocarditis |
| 2, 61/M (34) | None | AV | AMP (S), OFX (S), GEN (HLR) | NR | AMP + OFX (6) | AV replacement | Cure | 1 mo |
| 3, 68/M (4) | MV prosthesis | MV | AMP (S), GEN (S) | VanAr | AMP (8) + GEN (6) | MV replacement | Cure | 4 mo |
| 4, 68/M (3) | Rheumatic heart disease, AV prosthesis, MV prosthesis | Undefined | PEN (S), AMP (S), GEN (S) | VanAr | AMP + GEN (6) | No | Cure | 3 mo |
| 5, 64/M (7) | None | PV | AMP (R), GEN (R) | NR | LZD (6) | No | Death | Death 1 wk after completion of linezolid |
| 6, 79/F (35) | MV prosthesis | Undefined | AMX (S), GEN (S), LZD (S) | VanAr | LZD (12) + GEN (6) | No | Cure | 52 mo |
| 7, 37/F (this study) | None | AV, MV | PEN (S), AMP (S), STR (S), GEN (HLR), LZD (S), DAP (S) | VanAr | PEN + STR (6) | No | Cure | 9 mo |
a
M, male; F, female.
b
AV, aortic valve; MV, mitral valve; PV, pulmonic valve.
c
In vitro susceptibility data for VR E. faecalis isolates; antibiotic therapy, final antibiotic regimen; S, susceptible; R, resistant; HLR, high-level resistance to gentamicin (MIC, >500 μg/ml); AMP, ampicillin; AMX, amoxicillin; CIP, ciprofloxacin; DAP, daptomycin; GEN, gentamicin; LZD, linezolid; OFX, ofloxacin; PEN, penicillin; STR, streptomycin.
d
NR, not reported.
e
Follow-up, follow-up time without relapse after completion of antibiotic therapy, unless otherwise specified.